書目名稱Depressive Disorders: Mechanisms, Measurement and Management影響因子(影響力)學(xué)科排名
書目名稱Depressive Disorders: Mechanisms, Measurement and Management網(wǎng)絡(luò)公開度
書目名稱Depressive Disorders: Mechanisms, Measurement and Management網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Depressive Disorders: Mechanisms, Measurement and Management被引頻次
書目名稱Depressive Disorders: Mechanisms, Measurement and Management被引頻次學(xué)科排名
書目名稱Depressive Disorders: Mechanisms, Measurement and Management年度引用
書目名稱Depressive Disorders: Mechanisms, Measurement and Management年度引用學(xué)科排名
書目名稱Depressive Disorders: Mechanisms, Measurement and Management讀者反饋
書目名稱Depressive Disorders: Mechanisms, Measurement and Management讀者反饋學(xué)科排名
作者: crucial 時(shí)間: 2025-3-21 21:04 作者: stress-response 時(shí)間: 2025-3-22 01:48 作者: moribund 時(shí)間: 2025-3-22 04:58
https://doi.org/10.1007/978-3-030-62859-8cide, and so on. Its etiology remains vague but it is believed that depressive disorder is a multifactorial disease which is induced by the interaction of social, psychological, and biological factors. Thus, there is no clear and definite pathological theory could illustrate its mechanism independen作者: 許可 時(shí)間: 2025-3-22 12:08 作者: Addictive 時(shí)間: 2025-3-22 13:13 作者: Addictive 時(shí)間: 2025-3-22 18:15 作者: detach 時(shí)間: 2025-3-22 22:56 作者: Palpitation 時(shí)間: 2025-3-23 04:25 作者: thrombosis 時(shí)間: 2025-3-23 07:13 作者: 多產(chǎn)魚 時(shí)間: 2025-3-23 13:03
Interdisciplinary Studies in Human Rightsy that happened in early life is found to be deleterious to individual’s physical and mental health, which is highly related to depressive disorders onset. Stressful life events are consistently considered to be the high-risk factors of environment for predisposing depressive disorders. In linking s作者: jovial 時(shí)間: 2025-3-23 14:46 作者: 難解 時(shí)間: 2025-3-23 21:49
EU Integrated Urban Initiatives], transcranial magnetic stimulation [TMS], etc.). The updated CANMAT guidelines recommended the most second-generation antidepressants as first-line treatments for patients with a major depressive disorder (MDD) of moderate or greater severity. Before antidepressant treatment, comprehensive assessm作者: CALL 時(shí)間: 2025-3-23 22:28
EU Integrated Urban Initiativesission after the first or second trial of pharmacotherapy. Those who failed standard antidepressant treatment are termed as Treatment-Resistant Depression (TRD). Pharmacotherapy for TRD is more viable over past 15?years in part due to advances in clinical trials such as the Sequenced Treatment Alter作者: 魅力 時(shí)間: 2025-3-24 04:57
Product Liability and Digital Productscurrence. However, a large proportion of patients do not experience symptomatic remission after the initial treatment, with even lower rates of remission in the longer treatment term. The main objective of individualized treatment applied in psychiatry is to improve precision in disease diagnosis, p作者: 一大群 時(shí)間: 2025-3-24 10:30 作者: 男生如果明白 時(shí)間: 2025-3-24 12:45 作者: 起波瀾 時(shí)間: 2025-3-24 16:19
Rolf H. Weber,Dominic N. Staigerive medications, including inadequate treatment response, the therapeutic lag between drug administration and the onset of symptoms alleviation, and the safety consideration limit their clinical use and accelerate the exploration of advanced antidepressants with novel action mechanisms/newer targets作者: 拍下盜公款 時(shí)間: 2025-3-24 22:17
https://doi.org/10.1007/978-981-32-9271-0Depression; Biological advance; Clinical practice; Therapeutic strategy; Course management作者: Exploit 時(shí)間: 2025-3-25 02:14 作者: 興奮過度 時(shí)間: 2025-3-25 05:39
https://doi.org/10.1007/978-3-030-62859-8rmacotherapy, psychotherapy, and physical therapy. For now, anti-depressants used in clinical practice is almost monoamine-based drugs while much more progress have been made in developing new antidepressant medications, like prototypical N-methyl-D-aspartate (NMDA) receptor antagonists, opioid agon作者: 事與愿違 時(shí)間: 2025-3-25 09:19 作者: 連系 時(shí)間: 2025-3-25 14:06
Interdisciplinary Studies in Human Rightst in patients with MDD. Monoamine antidepressants and lithium are attributed to regulation of biological rhythm. And some rhythm-regulated agents have been shown efficacy of antidepressant. Considering the crucial clinical significance of disturbed biological rhythms in MDD, we describe the mechanis作者: 異教徒 時(shí)間: 2025-3-25 17:08
Interdisciplinary Studies in Human Rightsluding polymorphism of ., ., ., ., ., and .. Meanwhile, stressful life experience particularly early life stress will exert epigenetic modification in these risk genes via DNA methylation and miRNA regulation to generate long-lasting effects on these genes expression, which in turn cause brain struc作者: 易受刺激 時(shí)間: 2025-3-25 23:07 作者: flourish 時(shí)間: 2025-3-26 01:43
EU Integrated Urban Initiativesthium, Triiodothyronine (T3), Aripiprazole, Brexpiprazole, Quetiapine, and Olanzapine in combination with Fluoxetine. Many works need to be done to further advance this field. These include (1) Establish agreement on a standardized, systematic, and feasible definition of TRD, (2) Establish safety an作者: ICLE 時(shí)間: 2025-3-26 06:00
Product Liability and Digital Productsrognosis. Especially in the choice of intervention, individualized treatment should be considered. In this review, we present the development of precise treatment in depressive disorders and introduce advances in several domains toward precision medicine and individualized treatment. We pay particul作者: corn732 時(shí)間: 2025-3-26 09:50 作者: modifier 時(shí)間: 2025-3-26 15:31 作者: 終止 時(shí)間: 2025-3-26 19:14
Correction to: Neuroimmune Advance in Depressive Disorder,作者: 做事過頭 時(shí)間: 2025-3-26 23:02 作者: 紅腫 時(shí)間: 2025-3-27 04:06
0065-2598 ement and management of depressive disorder. It will help postgraduate students and academic researchers to get either basic or clinical picture of depressive disorder. Also, it may benefit pharmaceutical companies for developing novel drugs to treat this disease.??.978-981-32-9273-4978-981-32-9271-0Series ISSN 0065-2598 Series E-ISSN 2214-8019 作者: Spina-Bifida 時(shí)間: 2025-3-27 05:27 作者: TERRA 時(shí)間: 2025-3-27 09:39
Neuroimaging Advance in Depressive Disorder,ent outcomes. In this chapter, we conclude neuroimaging studies in the research field of depression from psychopathological, molecular, genetic/environmental, diagnostic, and therapeutic perspectives.作者: 過于光澤 時(shí)間: 2025-3-27 14:56 作者: itinerary 時(shí)間: 2025-3-27 21:46
Advance in Stress for Depressive Disorder,luding polymorphism of ., ., ., ., ., and .. Meanwhile, stressful life experience particularly early life stress will exert epigenetic modification in these risk genes via DNA methylation and miRNA regulation to generate long-lasting effects on these genes expression, which in turn cause brain struc作者: 不開心 時(shí)間: 2025-3-27 22:23
Standardized Treatment Strategy for Depressive Disorder,prove the efficacy for patients with treatment-resistant depression (TRD). To prevent the relapse and recurrence of disease, the long-term treatment comprised of acute treatment, consolidation treatment, and maintenance treatment must be considered for all patients.作者: 羊欄 時(shí)間: 2025-3-28 03:02 作者: 吸引人的花招 時(shí)間: 2025-3-28 07:03
Individualized Treatment Strategy for Depressive Disorder,rognosis. Especially in the choice of intervention, individualized treatment should be considered. In this review, we present the development of precise treatment in depressive disorders and introduce advances in several domains toward precision medicine and individualized treatment. We pay particul作者: harpsichord 時(shí)間: 2025-3-28 11:42 作者: Malaise 時(shí)間: 2025-3-28 16:26 作者: disrupt 時(shí)間: 2025-3-28 21:55
Book 2019stgraduate students and academic researchers to get either basic or clinical picture of depressive disorder. Also, it may benefit pharmaceutical companies for developing novel drugs to treat this disease.??.作者: 山頂可休息 時(shí)間: 2025-3-29 00:43
https://doi.org/10.1007/978-90-6704-823-1gress in the genetics of major depression and bipolar disorder has been made. This article reviews the candidate genes for MDD and BD, genetic variation loci, chromosome structural variation, new technologies, and new methods.作者: choleretic 時(shí)間: 2025-3-29 04:33
https://doi.org/10.1007/978-3-030-20607-9excessive negative focus. Revealing the molecular, cellular, and circuit properties of the LHb will help explain how abnormalities in LHb activity are linked to depressive disorders and shed light on developing novel strategies for depression treatment.作者: PAD416 時(shí)間: 2025-3-29 10:05
Genetic Advance in Depressive Disorder,gress in the genetics of major depression and bipolar disorder has been made. This article reviews the candidate genes for MDD and BD, genetic variation loci, chromosome structural variation, new technologies, and new methods.作者: Capitulate 時(shí)間: 2025-3-29 13:30 作者: Virtues 時(shí)間: 2025-3-29 18:18 作者: INCUR 時(shí)間: 2025-3-29 20:11
Internet-Based Management for Depressive Disorder,l practice. The eMBC strengthens MBC through web/mobile devices and telephone consulting services, to monitor disease progression, and customizes the MBC interface in electronic medical record systems (EMRs).作者: CALL 時(shí)間: 2025-3-30 02:25 作者: 妨礙議事 時(shí)間: 2025-3-30 04:49
Rolf H. Weber,Dominic N. Staigerl practice. The eMBC strengthens MBC through web/mobile devices and telephone consulting services, to monitor disease progression, and customizes the MBC interface in electronic medical record systems (EMRs).作者: 抗原 時(shí)間: 2025-3-30 10:50
0065-2598 logical, molecular and genomic mechanisms that drive depress.This book offers a state-of-the-art report on recent discoveries concerning the basic and clinical, neuroscientific and psychiatric findings in depression research. Depressive disorder is a severe and recurrent brain disorder that can mani作者: 止痛藥 時(shí)間: 2025-3-30 16:20 作者: 小步走路 時(shí)間: 2025-3-30 18:43 作者: 賞心悅目 時(shí)間: 2025-3-30 21:00 作者: 古代 時(shí)間: 2025-3-31 02:28
Neuroimmune Advance in Depressive Disorder,ns have been known as risk factors in the pathogenesis of MDD. In the meantime, accumulating evidence has suggested that some interventions targeting the inflammatory processes may play an important role in the treatment of MDD.
